Helios Gene Gun Particle Delivery for Therapy of Acid Maltase Deficiency

Martiniuk, Frank; Chen, Agnes; Mack, Adra; Donnabella, Vincent; Slonim, Alfred; Bulone, Linda; Arvanitopoulos, Eleni; Raben, Nina; Plotz, Paul; Rom, William N.
October 2002
DNA & Cell Biology;Oct2002, Vol. 21 Issue 10, p717
Academic Journal
Autosomal recessive deficiency of lysosomal acid maltase (GAA) or glycogen storage disease type II (GSDII) results in a spectrum of phenotypes including a rapidly fatal infantile disorder (Pompe's), juvenile, and a late-onset adult myopathy. The infantile onset form presents as hypotonia with massive accumulation of glycogen in skeletal and heart muscle, with death due to cardiorespiratory failure. Adult patients with the slowly progressive form develop severe skeletal muscle weakness and respiratory failure. Particle bombardment is a safe, efficient physical method in which high-density, subcellular-sized particles are accelerated to high velocity to carry DNA into cells. Because it does not depend on a specific ligand, receptor, or biochemical features on cell surfaces, particle-mediated gene transfer can be readily applied to a variety of systems. We evaluated particle bombardment as a delivery system for therapy of GSDII. We utilized a vector carrying the CMV promoter linked to the human GAA cDNA. Human GSDII cell lines (fibroblasts and lymphoid) as well as ex vivo with adult-onset peripheral blood cells (lymphocytes and monocytes) were transiently transfected by bombardment with a Helios gene gun delivering gold particles coated with the GAA expression plasmid. All cell types showed an increase in human GAA activity greater than 50% of normal activity. Subsequently, GAA -/- mice were treated every 2 weeks for 4 months by particle bombardment to the epidermis of the lower back and hind limbs. Muscle weakness in the hind and forelimbs was reversed. These data suggest that particle delivery of the GAA cDNA by the Helios gene gun may be a safe, effective treatment for GSDII.


Related Articles

  • Novel Treatment for Neuronopathic Lysosomal Storage Diseases-Cell Therapy / Gene Therapy. Eto, Yoshikatsu; Ohashi, Toya // Current Molecular Medicine;Feb2002, Vol. 2 Issue 1, p83 

    Most lysosomal storage diseases (LSD) exhibit neurological symptoms and there has been limited success in their treatment. Innovative treatments employing novel therapy or gene therapy may offer the prospect of improvement. Recent attempts to treat the neurological forms of LSD include neural...

  • Gene Therapy for Lysosomal Storage Diseases. Sands, Mark S.; Davidson, Beverly L. // Molecular Therapy;May2006, Vol. 13 Issue 5, p839 

    Lysosomal storage diseases (LSDs) comprise a diverse group of monogenetic disorders with complex clinical phenotypes that include both systemic and central nervous system pathologies. In recent years, the identification or development of mouse models recapitulating the clinical course of the...

  • Metachromatic leukodystrophy: an overview of current and prospective treatments. Biffi, A.; Lucchini, G.; Rovelli, A.; Sessa, M. // Bone Marrow Transplantation;Oct2008 Supplement, Vol. 42, pS2 

    Nowadays, different treatment options are available for an extending list of lysosomal storage diseases (LSDs). Hematopoietic stem cell transplantation (HSCT) can benefit selected subsets of patients with some LSDs, but results have been poor in several other disorders, including metachromatic...

  • Novel Therapies.  // Current Medical Literature: Lysosomal Storage Disease;2013, Vol. 11 Issue 4, p122 

    The article presents multiple opinions on novel therapies of lysosomal storage diseases (LSDs). Kay MacDermot's commentaries concern the use of bicyclic derivatives of L-idonojirimycin for certain forms of Gaucher disease (GD). MacDermot also expresses his opinion on a gene therapy to the...

  • Treatment of Fabry Disease: Current and Emerging Strategies. Rozenfeld, Paula; Neumann, Pablo M. // Current Pharmaceutical Biotechnology;Jun2011, Vol. 12 Issue 6, p916 

    No abstract available.

  • CITATIONS AND CLINICIANS' NOTES: TREATMENT -- NOVEL THERAPIES.  // Current Medical Literature: Lysosomal Storage Disease;2004, Vol. 4 Issue 2, p50 

    Presents clinicians' notes for novel therapies for lysosomal storage diseases. Photochemical internalization in drug and gene delivery; Treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation; Role of genetic vectors on the successful application of gene therapy for...

  • Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Desnick, Robert J.; Schuchman, Edward H. // Nature Reviews Genetics;Dec2002, Vol. 3 Issue 12, p954 

    The past decade has witnessed remarkable advances in our ability to treat inherited metabolic disorders, especially the lysosomal storage diseases, a group of more than 40 disorders, each of which is caused by the deficiency of a lysosomal enzyme or protein. During the past few years, both...

  • Citations and Clinicians' Notes: Treatment | Enzyme Replacement Therapy.  // Current Medical Literature: Lysosomal Storage Disease;2003, Vol. 3 Issue 2, p56 

    Presents clinicians' notes on enzyme replacement therapy for lysosomal storage diseases. Rebound hepatosplenomegaly in type 1 Gaucher disease; Clinical effect of enzyme replacement therapy in Anderson-Fabry disease; Immune tolerance after long-term enzyme-replacement therapy among patients who...

  • Citations and Clinicians' Notes: Treatment | Novel Therapies.  // Current Medical Literature: Lysosomal Storage Disease;2003, Vol. 3 Issue 2, p58 

    Presents clinicians' notes on novel therapies for lysosomal storage diseases. Hematopoietic cell transplantation for inherited metabolic diseases; Clinical trial of a formulation of a topical cysteamine for the treatment of corneal cystine crystals in cystinosis; Uptake of recombinant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics